SRx Health Solutions, EMJX Invest in Optimi Health’s 5.6M Shares With 30% Insider Ownership
SRXH•SRx Health Solutions and EMJ Crypto Technologies invested in Optimi Health, a GMP-grade, commercial-stage psychedelics company with 5.6 million shares outstanding and 30% insider ownership. The deal follows a presidential order in April 2026 to accelerate psychedelic drug development and taps EMJX’s AI-driven quantitative investment platform.
1. Investment Partnership
SRx Health Solutions and EMJ Crypto Technologies have invested in Optimi Health Corp, a commercial-stage pharmaceutical company manufacturing GMP-grade psychedelic products for mental health therapies. The partnership follows SRx’s merger agreement with EMJX and marks their entry into the psychedelics sector.
2. Ownership and Structure
Optimi Health has approximately 5.6 million shares outstanding, with about 30% held by insiders, and significant institutional participation. Governance is led by Chairman JJ Wilson, whose family founded Lululemon, underscoring strong insider alignment.
3. Industry Tailwinds
A presidential order in April 2026 aims to accelerate psychedelic drug development by improving FDA and DEA coordination, creating favorable regulatory momentum. This directive is expected to shorten approval timelines for companies like Optimi Health.
4. Transaction Process
SRx Health Solutions has filed a Registration Statement on Form S-4 to register shares for the proposed transaction with EMJX. Once declared effective, a definitive information statement and prospectus will be distributed to shareholders for approval.
